Christopher R. Flowers, MD, discusses the current therapies used for patients with relapsed/refractory diffuse large B-cell lymphoma and goes into specifics of the L-MIND trial after the long-term follow-up.
Videos
Haris Ali, MD, a hematology oncologist at the City of Hope Comprehensive Cancer Center, discusses common myeloproliferative neoplasms driver mutations.
The rationale for treating patients with advanced urothelial carcinoma with sacituzumab govitecan, a novel antibody-drug conjugate now approved that targets Trop-2.
Ruben Mesa, MD, and John Mascarenhas, MD, discuss whether therapies with a clinically meaningful impact on myelofibrosis may have a survival advantage for patients.
Expert hematologist/oncologists comment on the value of reducing fibrosis as a potential goal of therapy when treating patients with myelofibrosis.
Reactions to the availability of antibody-drug conjugates as later-line therapy for patients with metastatic urothelial carcinoma, and potential considerations for adopting enfortumab vedotin into clinical practice.
Peter Riedell, MD, an assistant professor of medicine at University of Chicago Medicine, discusses outcomes for mantle cell lymphoma patients and the impact of the timing of relapse on overall survival after autologous stem cell transplantation.
Bishoy M. Faltas, MD, Fellow, Hematology/Oncology, Weill Cornell Medical College, discusses genomic testing in urothelial cancer.
Dr Evan Y. Yu shares sequencing strategies for LuPSMA radioligand therapy in patients with PSMA-positive mCRPC.
Evan Y. Yu, MD, reviews the phase 2 TheraP trial evaluating PSA response in patients with PSMA-positive mCRPC who received LuPSMA therapy vs cabazitaxel.
An expert in prostate cancer comments on patient response to 177Lu-PSMA-617 therapy, particularly for patients with mCRPC who have liver metastases.
Dr Evan Y. Yu reviews the use of 177Lu-PSMA-617 therapy in patients with progressive PSMA-positive mCRPC as seen in the phase 3 VISION trial.
Evan Y. Yu, MD, shares insight on the rationale for precision medicine in patients with progressive PSMA-positive metastatic castration resistant prostate cancer (mCRPC) who have been previously treated with androgen axis inhibitor drugs and taxane.
Thomas G. Martin, MD, discusses the use of anti-CD38 antibodies in patients with multiple myeloma.
Jorge Nieva, MD, discusses the results of the Impower010 study, which evaluated the efficacy of the checkpoint inhibitor atezolizumab after chemotherapy for lung cancer compared to best supportive care.
Joel Neal, MD, PhD, and Alexander I Spira, MD, PhD, FACP, review current treatments for EGFR Exon 20 Insertion+ NSCLC, their preferred treatments, and current clinical trials.
Experts review the demographics of patients who should be tested and how to discuss EGFR Exon 20 Insertion+ NSCLC with patients.
Thomas Marron, MD, PhD an assistant professor of hematology and medical oncology at Mount Sinai Hospital, discusses the study design and key goals of adding perioperative cemiplimab, an anti-PD-1 antibody, to surgical resection for hepatocellular carcinoma.
Yael Simons, MD, discusses the study of somatic driver gene alterations in a consecutive series of luminal breast tumors in Black patients, which received an American Society of Clinical Oncology Merit Award.
Considerations for ongoing clinical trials that may shape the future treatment landscape of unresectable hepatocellular carcinoma.
Richard Kim, MD, shares insight on positive results from IMbrave150, which tested the frontline combination of atezolizumab and bevacizumab in patients with unresectable HCC.
A brief synopsis on optimal sequencing strategies for patients who have been diagnosed with unresectable hepatocellular carcinoma.
A comprehensive overview of the frontline treatment landscape for patients with unresectable HCC, including those who present with contraindications to standard-of-care therapy.
Drs John Mascarenhas and Ruben Mesa review unmet needs and challenges in treating myelofibrosis.
Second-line treatment approaches available for metastatic urothelial carcinoma and considerations for switching therapies vs re-challenging with prior therapy.
What to know regarding molecular testing assays used to assess patients with metastatic urothelial carcinoma.
Ruben Mesa, MD, and John Mascarenhas, MD, review the patient selection of extended molecular panels and the appropriate interval for molecular profiling for the management of myelofibrosis.
Shannon Westin, MD, MPH, FACOG, a gynecologic oncologist at The University of Texas MD Anderson Cancer Center, discusses the use of durvalumab with or without olaparib for the treatment of endometrial cancers.
Ghasson K. Abou-Alfa, MD, discusses that phase 2 study of tislelizumab as treatment of patients with unresectable hepatocellular carcinoma.
Expert Richard Kim, MD, reflects on the nature of HCC, particularly the challenges inherent in diagnosis and management.